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BACKGROUND
Convalescent plasma is frequently administered to patients with Covid-19 and has 
been reported, largely on the basis of observational data, to improve clinical outcomes. 
Minimal data are available from adequately powered randomized, controlled trials.
METHODS
We randomly assigned hospitalized adult patients with severe Covid-19 pneumonia 
in a 2:1 ratio to receive convalescent plasma or placebo. The primary outcome was 
the patient’s clinical status 30 days after the intervention, as measured on a six-point 
ordinal scale ranging from total recovery to death.
RESULTS
A total of 228 patients were assigned to receive convalescent plasma and 105 to 
receive placebo. The median time from the onset of symptoms to enrollment in 
the trial was 8 days (interquartile range, 5 to 10), and hypoxemia was the most 
frequent severity criterion for enrollment. The infused convalescent plasma had a 
median titer of 1:3200 of total SARS-CoV-2 antibodies (interquartile range, 1:800 to 
1:3200]. No patients were lost to follow-up. At day 30 day, no significant difference 
was noted between the convalescent plasma group and the placebo group in the 
distribution of clinical outcomes according to the ordinal scale (odds ratio, 0.83 
(95% confidence interval [CI], 0.52 to 1.35; P = 0.46). Overall mortality was 10.96% 
in the convalescent plasma group and 11.43% in the placebo group, for a risk dif-
ference of −0.46 percentage points (95% CI, −7.8 to 6.8). Total SARS-CoV-2 antibody 
titers tended to be higher in the convalescent plasma group at day 2 after the inter-
vention. Adverse events and serious adverse events were similar in the two groups.
CONCLUSIONS
No significant differences were observed in clinical status or overall mortality be-
tween patients treated with convalescent plasma and those who received placebo. 
(PlasmAr ClinicalTrials.gov number, NCT04383535.)
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In late 2019, the severe acute respira-tory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, and has spread 
worldwide since then, infecting millions of peo-
ple. Coronavirus disease 2019 (Covid-19), the dis-
ease caused by SARS-CoV-2, has clinical manifesta-
tions ranging from no symptoms to respiratory 
failure. So far, only two agents have shown a 
degree of clinical efficacy in large randomized, 
controlled trials: remdesivir, in hospitalized pa-
tients with pulmonary disease, and dexametha-
sone, in hospitalized patients receiving oxygen.1,2
Convalescent plasma has been used for the 
treatment of infectious diseases for more than a 
century, under the assumption that passive im-
munization can “jump start” the immune sys-
tem to control the evolution of the disease until 
a specific immune response is established in the 
infected person.3 Despite great interest, conva-
lescent plasma has been clearly demonstrated to 
be of value only in the treatment of Argentine 
hemorrhagic fever, for which it is considered stan-
dard of care.4 Although predominantly open-label, 
nonrandomized trials have claimed efficacy of 
convalescent plasma in SARS, Middle East respi-
ratory syndrome (MERS), influenza A (H1N1) in 
2009, avian influenza (H5N1) and Ebola, conclu-
sive data from randomized, controlled trials are 
lacking.5-8
Observational studies have consistently shown 
that convalescent plasma has an adequate safety 
profile in patients with Covid-19. An exploratory 
analysis in 4330 patients showed no significant 
difference in 7-day mortality between patients 
who received high-titer plasma and those who 
received low-titer plasma in the overall population, 
whereas 20% lower 7-day mortality was seen in 
the predefined subgroup of nonintubated patients 
who received higher-titer plasma than in those 
who received lower-titer plasma (14%, vs. 11%; 
P = 0.03). In a post hoc analysis, 7-day mortality 
in nonintubated patients who were younger than 
80 years of age and were treated within 72 hours 
after diagnosis was 6.3% in those receiving high-
titer plasma and 11.3% in those receiving low-titer 
plasma (P = 0.0008).9 A similar efficacy analysis 
from the Mayo Clinic included 3082 participants 
receiving a single unit of plasma among the 
35,322 patients who had received plasma through 
the expanded-access program.10 After adjustment 
for baseline characteristics, the 30-day mortality 
rate was 29.1% in the low-titer group and 24.7% in 
the high-titer group; the difference did not reach 
statistical significance. A post hoc subgroup analy-
sis also suggested a benefit of high-titer plasma in 
patients who received plasma within 3 days after 
Covid-19 diagnosis. On the basis of all available 
data, convalescent plasma is currently available 
for use in the United States under an Emergency 
Use Authorization (EUA) and has been widely 
used worldwide in the context of extended and 
compassionate use.11,12
In February 2020, the first imported case of 
Covid-19 was reported in Buenos Aires, and since 
then, the number of cases has been increasing 
steadily, reaching a total of more than 417,700 
cases by the end of August.13 In an attempt to 
more clearly determine the effect of convalescent 
plasma in Covid-19, we planned and conducted 
the PlasmAr trial to evaluate the safety and ef-
ficacy of convalescent plasma in the treatment of 
SARS-CoV-2 pneumonia. The main hypothesis of 
this trial was that in patients with severe SARS-
CoV-2 pneumonia, treatment with convalescent 
plasma would be associated with improved clinical 
outcomes at 30 days.
Patien t s a nd Me thods
Trial Design
PlasmAr was a double-blind, placebo-controlled, 
multicenter trial conducted at 12 clinical sites in 
Argentina and coordinated by Hospital Italiano 
de Buenos Aires. Eligible participants were ran-
domly assigned in a 2:1 ratio to receive either 
convalescent plasma or placebo. The trial protocol, 
available with the full text of this article at NEJM 
.org, was approved by the institutional review 
boards at all the clinical sites and by regional or 
jurisdictional ethics committees, as applicable. 
Written informed consent was obtained from all 
participants, and the trial was conducted in ac-
cordance with the principles stated in the Declara-
tion of Helsinki and Good Clinical Practice guide-
lines. The authors take full responsibility for the 
design and conduct of the trial and vouch for the 
accuracy and completeness of the data, the analy-
sis of the data, and the adherence of the trial to 
the protocol. No one who is not an author con-
tributed to the writing of the manuscript.
Inclusion and Exclusion Criteria
Hospitalized adults (at least 18 years of age) at 
each participating site were screened for enroll-
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ment if they had a reverse-transcriptase–poly-
merase-chain-reaction (RT-PCR) assay of a re-
spiratory tract sample that was positive for 
SARS-CoV-2, radiologically confirmed pneumo-
nia, no previous directives rejecting advanced 
life support, and at least one of the following 
severity criteria: oxygen saturation (SaO2) below 
93% while they were at rest and breathing ambi-
ent air, a ratio of the partial pressure of oxygen 
(PaO2) to the fraction of inspired oxygen (FiO2) 
below 300 mm Hg (PaO2:FiO2), or a Sequential 
Organ Failure Assessment (SOFA) or modified 
SOFA (mSOFA) score of two or more points above 
baseline status (scores range from 0 to 24, with 
higher scores indicating more severe disease). 
Patients who were pregnant or lactating, patients 
of reproductive age who were not willing to use 
contraceptive measures for a period of 30 days 
after enrollment, and patients with a history of 
blood component allergies, an infectious cause 
of pneumonia other than SARS-CoV-2, a require-
ment for mechanical ventilation, multiorgan fail-
ure, or any other condition that would impede the 
provision of informed consent were excluded.
Intervention
Eligible patients underwent treatment allocation 
and concealment through a randomization pro-
gram (REDCap)14 and were assigned in a 2:1 ratio 
to receive either a single administration of Covid-19 
convalescent plasma or placebo (normal saline 
solution) in addition to standard treatment. The 
entire clinical team, the data collectors, and the 
outcome adjudicators were unaware of the treat-
ment assignments. Patients were allowed to receive 
antiviral agents, glucocorticoids, or both accord-
ing to the standard of care at the provider health 
care institution. Convalescent patients with a 
minimum SARS-CoV-2 total antibody titer of 1:400 
were accepted as plasma donors after they had 
provided informed consent. Convalescent plasma 
was from a single donor or from a pool of two 
to five donors. Specific SARS-CoV-2 IgG anti-
body titer was measured in each convalescent 
plasma pool before transfusion. The total antibody 
titer goal in convalescent plasma was above 1:800 
in all cases. For details of the intervention, see the 
Supplementary Appendix, available at NEJM.org.
Clinical Outcomes
The primary outcome was clinical status 30 days 
after intervention, as represented by one of six 
mutually exclusive ordinal categories on an adapt-
ed version of the World Health Organization 
(WHO) clinical scale: 1 indicated death, 2 inva-
sive ventilatory support, 3 hospitalized with sup-
plemental oxygen requirement, 4 hospitalized 
without supplemental oxygen requirement, 5 dis-
charged without full return to baseline physical 
function, and 6 discharged with full return to 
baseline physical function.15 Secondary outcomes 
were the clinical status on the ordinal scale at 
days 7 and 14 and the time (in days) to discharge 
from the hospital, the time to discharge from 
the intensive care unit (ICU), the time to im-
provement in at least two categories on the ordi-
nal scale, the time to death, and the time to full 
functional recovery. The incidence of adverse 
events and serious adverse events was analyzed 
in the two groups. After the trial intervention, 
patients were followed in person during in-hos-
pital admission and by telephone after hospital 
discharge. Details regarding data collection, pa-
tient follow-up, randomization, the data blinding 
and masking process, and plasma donation, col-
Figure 1. Enrollment and Randomization.
334 Underwent randomization
448 Patients were assessed for eligibility
23 Were not included owing
to early trial implementation
issues
91 Were excluded
31 Declined to participate
37 Were unable to give 
consent for the trial
2 Were pregnant
4 Had alternative diagnosis
3 Were enrolled in another
trial
14 Had other reason
228 Were assigned to and received
convalescent plasma
106 Were assigned to receive placebo
105 Received placebo
1 Did not receive placebo owing
to withdrawal of informed consent
228 Were included in primary analysis 105 Were included in primary analysis
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Median age (IQR) — yr 62.5 (53–72.5) 62 (49–71)
Age category — no. (%)
<65 yr 126 (55.3) 54 (51.4)
≥65 to <80 yr 75 (32.9) 43 (41)
≥80 yr 27 (11.8) 8 (7.6)
Female sex — no. (%) 67 (29.4) 41 (39.0)
Median time to onset of symptoms (IQR) — days 8 (5–10) 8 (5–10)
Coexisting conditions — no. (%)
No other conditions 80 (35.1) 37 (35.2)
Body-mass index >30 104 (45.6) 52 (49.5)
Hypertension 111 (48.7) 48 (45.7)
Diabetes 40 (17.5) 21 (20)
Chronic obstructive pulmonary disease 23 (10.1) 2 (1.9)
Asthma 9 (3.9) 5 (4.8)
Chronic renal failure 10 (4.4) 4 (3.8)
Hematologic cancer 4 (1.8) 3 (2.9)
Solid tumors 23 (10.1) 11 (10.5)
Current tobacco use 6 (2.6) 6 (5.7)
Previous tobacco use 101 (44.3) 37 (35.2)
Congestive heart failure 8 (3.5) 3 (2.9)
Thromboembolic disease 5 (2.2) 2 (1.9)
Previous medications used — no. (%)
ACEI or ARB 2 69 (30.3) 32 (30.5)
Frequent or recent use of NSAID 37 (16.2) 13 (12.4)
Anticoagulation 14 (6.1) 6 (5.7)
Corticosteroids 7 (3.1) 2 (1.9)
Immunosuppressants 6 (2.6) 3 (2.9)
Statins 61 (26.8) 21 (20)
Laboratory values
Median total SARS-CoV-2 antibody titer (IQR) 1/50 (0–1:800) 1:50 (0–1:1600)
Negative total SARS-CoV-2 antibody titer — no./total no. (%) 65/145 (44.8) 34/70 (48.6)
Median d-dimer level (IQR) — ng/ml 697 (470–1150) 797 (550–1224)
Median ferritin level (IQR) — ng/ml 939 (441–1634) 645 (362–1180)
Severity inclusion criteria — no. (%)
Oxygen saturation <93% at FiO2 0.21 224 (98.2) 100 (95.2)
mSOFA or SOFA ≥2 32 (14) 17 (16.2)
Hospitalization area at enrollment — no. (%)
Emergency department 11 (4.8) 3 (2.9)
General ward 150 (65.8) 77 (73.3)
Critical care unit 67 (29.4) 25 (23.8)
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lection, processing, and storage are provided in 
the Supplementary Appendix.
IgG Titers and Neutralizing Antibody 
Measurements
End-point IgG titrations of specific antibodies 
against the SARS-CoV-2 spike and receptor-bind-
ing domain were performed with the COVIDAR 
Argentina Consortium enzyme-linked immuno-
sorbent assay (ELISA) test. Neutralizing activity 
was measured through a standardized replication-
defective pseudotyped particle system that mim-
ics entry of live SARS-CoV-2, as previously de-
scribed.16
Laboratory Evaluation
All the patients were tested for total IgG SARS-
CoV-2 antibodies against spike protein on day 0 
(before infusion) and subsequently on days 2, 7, 
and 14. Ferritin and d-dimer levels were analyzed 
at baseline and on day 14.
Statistical Analysis
The trial was designed to enroll 333 patients 
(222 in the plasma group and 111 in the placebo 
group). We calculated that this sample size 
would provide 80% power to detect a propor-
tional odds ratio of 1.8 for plasma as compared 
with placebo on the clinical ordinal scale at the 
0.05 (two-sided) level of significance.17 More 
details are provided in Table S1, available in the 
Supplementary Appendix. An odds ratio greater 
than 1.0 would correspond to more favorable out-
comes with the use of plasma as compared with 
placebo. The analysis was performed with the 
STATA statistical software, version 15.1 MP, Par-
allel Edition (StataCorp). See the Supplementary 
Appendix for details regarding the overall statis-




Between May 28 and August 27, 2020, a total of 
448 patients were assessed for inclusion criteria 
at 12 participating centers, and 334 patients were 
enrolled. One patient withdrew informed consent 
before receiving the intervention. Consequently, 
228 patients were assigned to convalescent plasma 
and 105 to placebo (Fig. 1), and each patient re-
ceived the assigned infusion.
The median age of the patient population was 






Use of oxygen supplementation devices (n=299) — no. (%)
Low-flow nasal cannula 146 (64.0) 70 (66.7)
Venturi or nonrebreather mask 49 (21.5) 16 (15.2)
High-flow nasal cannula 11 (4.8) 7 (6.7)
Noninvasive ventilatory support 0 0
Treatments during trial† — no. (%)
Supplemental oxygen 206 (90.4) 93 (88.6)
Glucocorticoids‡ 209 (91.7) 101 (96.2)
Lopinavir–ritonavir 7 (3.1) 3 (2.9)
Tocilizumab 6 (2.6) 8 (7.6)
Ivermectin 4 (1.8) 1 (1)
Hydroxychloroquine 1 (0.4) 0
*  ACEI or ARB 2 denotes angiotensin-converting-enzyme inhibitor or angiotensin-receptor blocker, mSOFA modified 
Sequential Organ Failure Assessment, and NSAID nonsteroidal antiinflammatory drug.
†  Remdesivir was not available in Argentina during the trial.
‡  Glucocorticoids included low-dose dexamethasone or equivalent doses of other glucocorticoids.
Table 1. (Continued.)
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the patients were men, and 64.9% had a coexist-
ing condition at entry into the trial. The median 
time from the onset of Covid-19 symptoms to 
enrollment was 8 days (interquartile range, 5 to 
10). An oxygen saturation below 93% while the 
patient was breathing ambient air was the most 
common severity criterion for enrollment, and 
more than 90% of the patients were receiving 
oxygen and glucocorticoids at the time of entry 
into the trial (Table 1).
The median volume of infused convalescent 
plasma was 500 ml (interquartile range, 415 to 
600). Of the 215 patients from whom a baseline 
total anti–SARS-CoV-2 IgG antibody level could 
be obtained, the median titer was 1:50 (interquar-
tile range, 0 to 1:800); 46.0% of patients had no 
detectable antibody level.
Total IgG and neutralizing SARS-CoV-2 anti-
body titers were also analyzed in the infused 
convalescent plasma pools, using the COVIDAR 
assay. The total IgG antibody median value of all 
pools was 1:3200 (interquartile range, 1:800 to 
1:3200). Analysis of SARS-CoV-2 neutralizing 
antibody titers was available for 125 of the in-
fused convalescent plasma doses (56%), with an 
80% inhibitory concentration median titer of 1:300 
(interquartile range, 1:136 to 1:511). The correla-
tion analysis between the total SARS-CoV-2 anti-







Odds Ratio  
or Hazard Ratio  
(95% CI) P value
Primary outcome, clinical status at 30 days — no. of patients (%) Odds ratio, 0.81  
(0.50–1.31)
0.396
Death 25 (11) 12 (11.4)
Invasive ventilatory support 19 (8.3) 10 (9.5)
Hospitalized with supplemental oxygen requirement 5 (2.2) 2 (1.9)
Hospitalized without supplemental oxygen requirement 8 (3.5) 1 (1)
Discharged without full return to baseline physical function 30 (13.2) 8 (7.6)
Discharged with full return to baseline physical function 141 (61.8) 72 (68.6)
Secondary Outcomes
Median time from intervention (IQR) — days
To hospital discharge 13 (8–30) 12 (7–ND) Subhazard ratio, 1  
(0.76–1.32)
—
To discharge from the ICU ND (8–ND) ND (6–ND) Subhazard ratio, 0.94  
(0.48–1.82)
—
To complete restoration of physical functions† 15 (9–ND) 15 (7–ND) Subhazard ratio, 0.89  
(0.66–1.18)
—
To start of invasive ventilation ND (9–ND) ND Subhazard ratio, 1.14  
(0.72–1.81)
—
To death ND ND Hazard ratio, 0.93  
(0.47–1.86)
—
To improvement of 2 categories in the ordinal outcome  
or hospital discharge within 30 days
12 (7–29) 12 (6–ND) Hazard ratio, 1  
(0.76–1.32)
—
Adverse events — no (%)
Any event 153 (67.1) 66 (62.9) Odds ratio, 1.21  
(0.74–1.95)
—
Serious event 54 (23.7) 19 (18.1) Odds ratio, 1.40  
(0.78–2.51)
—
Infusion-related event 13 (5.7) 2 (1.9) Odds ratio, 3.13  
(0.69–14.11)
—
*  ND denotes could not be determined.
†  Restitution refers to the patient’s status at baseline.
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body titer and the neutralizing antibody titer in 
the convalescent plasma pools is provided in the 
Figure S1.
Primary Outcome
At day 30, no significant difference was noted 
between the convalescent plasma group and the 
placebo group in the distribution of clinical out-
comes according to the ordinal scale (odds ratio, 
0.83; 95% confidence interval [CI], 0.52 to 1.35; 
P = 0.46) (Table 2 and Fig. 2). The assumption of 
the proportional odds ratio for the primary out-
come was supported by the nonsignificant re-
sults of the Brant test (P = 0.34). After adjustment 
for sex, history of COPD, and history of tobacco 
use, the odds ratio for the score on the ordinal 
scale between the convalescent plasma and place-
bo groups was 0.92 (95% CI, 0.59 to 1.42; P = 0.70).
Secondary Outcomes
The 30-day mortality was 10.96% (25 of 228 pa-
tients) in the convalescent plasma group and 
11.43% (12 of 105) in the placebo group, for a 
risk difference of −0.46 percentage points (95% 
CI, −7.8 to 6.8). No significant between-group 
differences in clinical status on the ordinal scale 
were seen either at day 7 (odds ratio, 0.88; 95% 
CI, 0.58 to 1.34) or at day 14 (odds ratio, 1.00; 
95% CI, 0.65 to 1.55) (Fig. 2 and Table S2). The 
median time from enrollment to hospital dis-
charge was 13 days (interquartile range, 8 to 30) 
in the convalescent plasma group and 12 days 
(interquartile range, 7 to 30) in the placebo 
group (subhazard ratio, 0.99; 95% CI, 0.75 to 
1.32). Throughout the trial, the proportion of 
ICU admissions and invasive ventilatory support 
requirements was 53.9% (123 of 228 patients) 
Figure 2. Clinical Outcomes among Patients Treated with Convalescent Plasma as Compared with Placebo.
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and 26.8% (61 of 228 patients), respectively, in 
the convalescent plasma group and 60% (63 of 
105 patients) and 22.9% (24 of 105 patients), 
respectively, in the placebo group. No significant 
differences were noted in the time to death or in 
the time to clinical improvement of at least two 
categories on the ordinal scale or hospital dis-
charge (Fig. 3 and Table 2).
No differences in ferritin and d-dimer levels 
were noted between the patient groups at day 14. 
Although baseline median titers were identical, 
patients receiving convalescent plasma had SARS-
CoV-2 total antibody levels that were higher at 
day 2 than levels in patients receiving placebo. 
No differences in antibody titers were noted at 
days 7 or 14 (Table S3).
Subgroup Analysis
The prespecified subgroup analyses failed to sug-
gest any credible subgroup effects. Convalescent 
plasma appeared to be associated with a worse 
clinical outcome in the subgroup of patients 
younger than 65 years of age. However, the rest 
of the outcome analyses for this subgroup did 
not show similar results (Fig. S2 and S3). Analy-
ses of the primary outcome and of clinical im-
provement of at least two ordinal categories in 
relation to total and neutralizing antibody titers 
in the infused plasma pools are provided in the 
Supplementary Appendix.
Safety Results
Infusion-related adverse events were slightly more 
common in the convalescent plasma group (4.8%; 
11 of 228 patients) than in the placebo group 
(1.9%; 2 of 105 patients) (odds ratio, 2.62; 95% CI, 
0.57 to 12.04). Five patients in the convalescent 
plasma group and none in the placebo group had 
nonhemolytic febrile reactions. No significant dif-
ferences were found in the overall incidence of 
adverse events (odds ratio, 1.21; 95% CI, 0.74 to 
1.95) or serious adverse events (Table 2 and Ta-
ble S4).
Discussion
The use of convalescent plasma did not result in 
a significant clinical benefit as compared with 
placebo in patients with severe Covid-19 pneu-
monia. Our trial ensured that more than 95% of 
the transfused convalescent plasma units had a 
total anti–SARS-CoV-2 antibody titer of at least 
1:800 and that the plasma volume infused had a 
correction factor according to the participant’s 
weight. This finding is in contrast to the find-
ings of a series of nonrandomized studies claim-
ing convalescent plasma to be of substantial 
benefit and illustrates the importance of random-
ized, controlled trials, especially in the context of 
a pandemic.18
Figure 3. Time to Death or to Improvement after Treatment with  
Convalescent Plasma or Placebo.
Shown are the Kaplan–Meier failure estimates of the time from interven-
tion (administration of convalescent plasma or placebo) to death or to  
improvement in at least two categories in the ordinal scale or hospital dis-
charge. The ordinal scale, an adapted version of the World Health Organi-
zation clinical scale, has six mutually exclusive categories ranging from  
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Our data are consistent with the recently pub-
lished results of a randomized, controlled trial 
in patients with moderate Covid-19 that showed 
no difference in severe disease or death at day 
30, although the intervention was not blinded 
and the infused convalescent plasma had very 
low titers of specific antibodies.19
In a randomized, open-label clinical study of 
treatment with convalescent plasma in patients 
with severe and life-threatening Covid-19 that 
had to be interrupted, Li et al. found no differ-
ences in the time to hospital discharge, clinical 
improvement, or day-28 mortality in comparison 
with placebo.20 An open-label randomized, con-
trolled clinical trial in the Netherlands was 
stopped prematurely owing to detection of base-
line neutralizing antibodies in 79% of the pa-
tients tested, with median titers similar to those 
of the donors.21 In this regard, for the 215 pa-
tients in the present trial in whom pretreatment 
SARS-CoV-2 measurements were made, titers were 
less than 1:50 in 46.0% of the patients. As ex-
pected, antibody titers trend higher in the inter-
vention group at day 2, but this difference was 
diluted later in the trial. The median SARS-CoV-2 
neutralizing antibody titers of the infused plasma 
in the PlasmAr trial were high, in concordance 
with the general recommendations of regulatory 
authorities.22 The ConPlas-19 trial, an open-label 
randomized, controlled trial also failed to com-
plete enrollment and thus cannot provide firm 
conclusions about efficacy.23
Our trial had a number of prespecified sub-
group analyses in an attempt to detect patient 
subpopulations for which previous reports had 
suggested that the use of convalescent plasma 
might have a potential benefit. No differences in 
favor of convalescent plasma were noted in either 
the primary or the secondary outcomes in any of 
these subgroups, including the 39 patients who 
received the intervention within 72 hours after 
the onset of symptoms. We did find a difference 
in the primary outcome, in favor of placebo, for 
patients younger than 65 years of age (odds ratio 
0.18; 95% CI, 0.06 to 0.54). Additional analysis 
of this subgroup failed to reveal any clear expla-
nation, and we interpret this as a chance finding, 
although further confirmation in other studies 
may be warranted.
Our trial has limitations. All enrolled patients 
had severe Covid-19 pneumonia. As such, no 
conclusion should be extrapolated to other clini-
cal groups, including patients with mild-to-
moderate cases of Covid-19 or patients with life-
threatening disease. The median time from the 
onset of symptoms to progression to respiratory 
failure is around 7 days.24 This time frame is simi-
lar to the median time from the beginning of 
symptoms to enrollment in our trial. Thus, no 
firm conclusion can be drawn regarding the po-
tential efficacy of passive immune therapy earlier 
than the median time of entry to this trial or in 
patients with milder forms of the disease. Indeed, 
studies with specific antibodies administered 
within 72 hours of Covid-19 diagnosis in patients 
with risk factors for severe disease are currently 
ongoing or planned.
Although the use of usual therapy was allowed 
in both groups, it was not standardized among 
participating sites. Nevertheless, no significant 
differences were detected in the subgroup analy-
ses performed in this trial. Dexamethasone or 
other glucocorticoids were heavily used in both 
trial groups.2 Nevertheless, no suggestion for in-
teraction between convalescent plasma and con-
comitant therapies was found.
Specific postinfusion reactions, such as trans-
fusion-associated cardiac overload and transfu-
sion-related acute lung injury, were difficult to 
assess and differentiate from Covid-19 progres-
sion in this spectrum of patients with severe pneu-
monia. Similarly, the true effect of fluid overload 
on cardiovascular function in these patients may 
have been underestimated. In addition, convales-
cent plasma therapy is intrinsically heterogeneous. 
Different antibody-response phenotypes and im-
mune signatures could have different effects on 
disease progression.25 A recent study suggests 
that some autoantibodies that have developed in 
patients with life-threatening Covid-19 may be 
harmful by decreasing interferon-mediated im-
mune responses.26
In our trial, the use of convalescent plasma 
therapy in addition to standard treatment in 
patients with severe pneumonia due to Covid-19 
did not reduce mortality or improve other clini-
cal outcomes at day 30 as compared with pla-
cebo. We believe the use of convalescent plasma 
as a standard of care in such patients should be 
reevaluated. Further studies regarding antibody 
therapy may be best focused on other popula-
tions or on interventions with other types of 
preparations, such as intravenous immunoglob-
ulin or anti–SARS-CoV-2 monoclonal antibodies.
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